Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetics of Canagliflozin in Amish Subjects
NCT02462421Phase 4Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- Jun 2015
- Primary completion
- Dec 2021
- Modality
- Small Molecules
01
Overview
Phase 4, open-label trial of canagliflozin in type 2 diabetes mellitus (T2DM), gout and hyperuricemia (4 arms), sponsored by University of Maryland, Baltimore. Primary endpoints: Urinary Excretion of Glucose at 24 hours and Change in Fractional Excretion of Uric Acid at 24 hours. Started Jun 2015; status: terminated.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)gouthyperuricemia
Beyond the preview
Go deeper on NCT02462421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02462421.